Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China Matt Burke2020-12-28T08:16:19-05:00December 28, 2020| Read More
Cullinan Oncology Completes $131.2 Million Series C Financing Cullinan Oncology Completes $131.2 Million Series C Financing Matt Burke2020-12-17T07:59:32-05:00December 17, 2020| Read More
Jon Wigginton MD Receives SITC Visionary Legacy Award Jon Wigginton MD Receives SITC Visionary Legacy Award Matt Burke2020-11-13T12:19:46-05:00November 13, 2020| Read More
Cullinan Oncology Appoints Jeff Trigilio as Chief Financial Officer Cullinan Oncology Appoints Jeff Trigilio as Chief Financial Officer root2020-11-13T10:09:14-05:00October 29, 2020| Read More
Cullinan Pearl Announces Presentation of Preliminary Safety and Efficacy of CLN-081 in EGFR Exon 20 NSCLC Patients at ESMO Virtual Congress 2020 Cullinan Pearl Announces Presentation of Preliminary Safety and Efficacy of CLN-081 in EGFR Exon 20 NSCLC Patients at ESMO Virtual Congress 2020 Matt Burke2020-09-17T08:47:26-05:00September 17, 2020| Read More
Cullinan Oncology, German Cancer Research Center (DKFZ) and the University of Tübingen Announce the Formation of Cullinan Florentine to Develop CLN-049, a Novel Bispecific Antibody for AML Cullinan Oncology, German Cancer Research Center (DKFZ) and the University of Tübingen Announce the Formation of Cullinan Florentine to Develop CLN-049, a Novel Bispecific Antibody for AML root2020-09-15T07:30:14-05:00September 15, 2020| Read More
Cullinan Oncology Launches Cullinan Amber to Pioneer Next-Generation Cytokine Fusion Proteins for Cancer Therapy Cullinan Oncology Launches Cullinan Amber to Pioneer Next-Generation Cytokine Fusion Proteins for Cancer Therapy root2020-07-22T17:52:30-05:00July 22, 2020| Read More
Cullinan Oncology and PDI Therapeutics Join Forces to Bring Novel, First-In-Class Immuno-Oncology Antibody into the Clinic through a $26M Series A Financing Cullinan Oncology and PDI Therapeutics Join Forces to Bring Novel, First-In-Class Immuno-Oncology Antibody into the Clinic through a $26M Series A Financing root2020-06-11T11:36:55-05:00June 11, 2020| Read More
Cullinan Oncology Completes $98.5 Million Series B Financing Cullinan Oncology Completes $98.5 Million Series B Financing root2020-06-03T16:12:17-05:00June 3, 2020| Read More
Cullinan Oncology Announces First Patients Dosed with Drug Candidates from Cullinan Apollo and Cullinan Pearl Cullinan Oncology Announces First Patients Dosed with Drug Candidates from Cullinan Apollo and Cullinan Pearl Matt Burke2019-12-18T21:30:52-05:00December 18, 2019| Read More
